Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Other Non-Current Assets: 2015-2024

Historic Other Non-Current Assets for Cartesian Therapeutics (RNAC) over the last 9 years, with Dec 2024 value amounting to $1.7 million.

  • Cartesian Therapeutics' Other Non-Current Assets rose 232.59% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year increase of 232.59%. This contributed to the annual value of $1.7 million for FY2024, which is 21.21% up from last year.
  • As of FY2024, Cartesian Therapeutics' Other Non-Current Assets stood at $1.7 million, which was up 21.21% from $1.4 million recorded in FY2023.
  • Cartesian Therapeutics' Other Non-Current Assets' 5-year high stood at $1.7 million during FY2024, with a 5-year trough of $1.3 million in FY2022.
  • Over the past 3 years, Cartesian Therapeutics' median Other Non-Current Assets value was $1.4 million (recorded in 2023), while the average stood at $1.5 million.
  • In the last 5 years, Cartesian Therapeutics' Other Non-Current Assets fell by 4.93% in 2022 and then rose by 21.21% in 2024.
  • Cartesian Therapeutics' Other Non-Current Assets (Yearly) stood at $1.4 million in 2020, then remained steady at $1.4 million in 2021, then dropped by 4.93% to $1.3 million in 2022, then increased by 5.03% to $1.4 million in 2023, then rose by 21.21% to $1.7 million in 2024.